|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Merck |
|---|---|
| Information provided by: | Merck |
| ClinicalTrials.gov Identifier: | NCT00308347 |
Purpose
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Nephropathy |
Drug: MK0954, losartan / Duration of Treatment: mean 3.4 years Drug: Placebo / Duration of Treatment: mean 3.4 years |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-Insulin Dependent Diabetes Mellitus and Nephropathy |
| Estimated Enrollment: | 1513 |
| Study Start Date: | June 1996 |
Eligibility| Ages Eligible for Study: | 31 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc. |
| ClinicalTrials.gov Identifier: | NCT00308347 History of Changes |
| Other Study ID Numbers: | 2006_020, MK0954-147 |
| Study First Received: | March 27, 2006 |
| Last Updated: | May 12, 2009 |
| Health Authority: | United States: Food and Drug Administration |
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Kidney Diseases Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Urologic Diseases Losartan |
Anti-Arrhythmia Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |